Market capitalization | $443.46m |
Enterprise Value | $269.98m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.24 |
P/S ratio (TTM) P/S ratio | 2.03 |
P/B ratio (TTM) P/B ratio | 0.51 |
Revenue growth (TTM) Revenue growth | -30.81% |
Revenue (TTM) Revenue | $217.95m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Ginkgo Bioworks forecast:
6 Analysts have issued a Ginkgo Bioworks forecast:
Sep '24 |
+/-
%
|
||
Revenue | 218 218 |
31%
31%
|
|
Gross Profit | 120 120 |
16%
16%
|
|
EBITDA | -457 -457 |
34%
34%
|
EBIT (Operating Income) EBIT | -517 -517 |
36%
36%
|
Net Profit | -651 -651 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Head office | United States |
CEO | Jason Kelly |
Employees | 1,218 |
Founded | 2008 |
Website | www.ginkgobioworks.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.